News

Janssen Biotech and Bristol-Myers Squibb will collaborate in a clinical trial program to evaluate the combination of Darzalex (daratumumab) and Opdivo (nivolumab) in multiple myeloma patients and in several solid tumors in Phase 1b and Phase 2 trials. Darzalex and Opdivo are two immunotherapy agents that are meant to boost…

Adding the proteasome inhibitor Velcade (bortezomib) to the standard therapy of Revlimid (lenalidomide) and dexamethasone — a triple combo therapy — significantly extends progression-free survival and overall survival of multiple myeloma patients, according to the results of a recent Phase 3 trial. The study, titled “Bortezomib with lenalidomide and dexamethasone…

Researchers have discovered a mechanism underlying the development of treatment resistance to proteasome inhibitors in multiple myeloma. Surprisingly, the mechanism also was linked to a complete switch in the genetic profile of a tumor — opening up for the possibility that drugs with entirely different ways of acting may be…

Cancer Treatment Centers of America (CTCA) recently began enrolling patients with cancer for the clinical trial study TAPUR — Targeted Agent and Profiling Utilization Registry. The trial is designed to deepen the understanding of how cancer drugs act, including those designed for myeloma, and to learn more about possible additional…

Early treatment with a combination of anti-cancer drugs in patients with smoldering myeloma, who are at high risk of developing multiple myeloma, may avoid disease progression to its full-blown state, according to the interim results of a Phase 2 clinical trial. The data was presented recently by researchers from the…

The monoclonal antibody Darxalex (daratumumab) was recently approved by the U.S. Food and Drug Administration (FDA), in combination with either Revlimid (lenalidomide) and dexamethasone, or Velcade (bortezomib) and dexamethasone, as a treatment for multiple myeloma patients who have received at least one prior therapy. Now, Diplomat Pharmacy, whose website identifies…

Aduro Biotech recently presented positive preclinical data showing that its monoclonal antibody, BION-1301, may successfully inhibit multiple myeloma tumor growth, survival, and resistance to other chemotherapy agents. The data, presented at the 58th American Society of Hematology Annual Meeting Dec. 3-6 in San Diego, showed that BION-1301 can effectively inhibit APRIL…

The results of a new clinical trial suggest that two extension treatments that are frequently added to standard therapy care in patients with multiple myeloma do not improve patients’ progression-free survival compared to the current standard practice alone. The results were presented at the 58th American Society of Hematology…

Patients with advanced multiple myeloma may benefit from bluebird bio’s novel CAR T-cell therapy bb2121, according to data presented at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany. The study, “Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA…

A technique called extracorporeal blood purification (EBP) could be used to remove certain molecules from the blood and potentially treat different conditions including multiple myeloma and kidney complications associated with it.